Tretment of psoriatic arthritis with extracellular vesicles

Treatment Of Knee Psoriatic Arthritis Using Combination Of Extracellular Vesicles Enhanced Platelet Rich Plasma with Mobithron Advance : A Case Study

Sivamuralitharan Muniandy¹

Joshua Jude Solomon¹

Maagesswary Ravindran¹

Nivasini Muniandy¹

¹Dr

BackgroundPatient with psoriasis may present with osteoarthritis because of knee inflammation and most common treatment for psoriasis is based on steroid. Platelet Rich Plasma (PRP) used in early form of knee osteoarthritis but the result will be affected by long term steroid usage which are commonly used to treat psoriasis.   Mobithron Advance is a combination of hyaluronic acid matrix, undenatured type 11 collagen Boswellia serrata gum extract. We aim to see changes in terms of reduction of pain and radiological evidence by using intra articular knee injection combining PRP and extracellular vesicles. We aim to show that combination of PRP with exosome can still produce regenerative changes at knee joint in patients who are using low dose DMARD

MethodsPatient is a 59 years old female who had long-standing bilateral knee pain and skin rashes. The skin rashes were suggestive of guttate psoriasis. She was previously treated with Momethasone cream, prednisolone tablet 10mg daily and NSAIDS for painkiller. We gradually reduced her steroid and introduced tablet sulfasalazine 500mg daily. We also started Mobithron Advance. After 2 months, she was given intra articular injection of PRP and 25 billion particles of extracellular particles for each knee. She was reviewed after 2 months using standing knee xray and symptoms assessment

Results:

Initial Xray- Reduced Knee joint space bilaterally with osteophytes. Kellgren Lawrence grade 4Xray (after 2 months)- Marked increase in joint space. Kellgren Larence grade 2Initial pain score – 7/10. Pain score after 2 months – 2/10

Conclusion1. Combination of PRP with extracellular vesicles Mobithron Advance able to regenerate knee cartilage tissue even when given with low dose DMARD2. MARD dose can be optimize after adequate improvement seen to prevent further inflammation.

Acknowledgment

Mobithron Advance is product manufactured and distributed by Brego Life Sciences Pvt Lmt. Extracellular Vesicles supplied by Blisscell Pvt Lmt

References:

• Shalini V. Vanni D, Pantolone A, Abate M. Platelet Rich Plasma Therapy in Non insertional Archilles Tendinopathy. Frontiers in aging neuroscience 2015;7.228

• Oeding J.F, N.H Varaday, F.w Fearington, A Paraek, S.M Strickland. B.u Nwachukwu, C.L Camp and A.J Krych (2024). Platelet Rich Plasma verses Alternative Injections for Osteoarthritis of the knee. A systemic review and Statical Fragility Index- Based Meta- Analysis Of Randomized control Trial > Am J Sports Med :3635465231224463

• Chen CPC, Cheng CH, Lin HC, Tsai YR, Chen JL. The influence of platelet rich plasma on synovial fluid volumes, protein concentrations and severity of pain in patients with knee osteoarthritis. Experimental gerontology 2017;93:68-72

• Illayaraja Krishnan, Alvin Man lung Chan,Jia Xian LAw, Min Hwei Ng, Jaime Jacquline Jayapalan and Yogeswaran Lokanathan. Proteomic Analysis of Umblical Cord Mesenchymal Stem Cell- Derived Extracellular Vesicles : A Systemic Review. International Journal of Molecular Science 2024,25,5340

Keywords: psoriasisosteoarthritisplatelet rich plasmaextracellular vesicles